W
WAVEMAN · COMPANY
TELA · Tela Bio, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

TELA

TELA Bio, Inc.
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001561921
ACTIVIST 13DC-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$18.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
21
13F, latest reported quarter
REVENUE GROWTH
+15.8%
XBRL, annual
NET MARGIN
-48.4%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$18.8K over 180 days
+$18.8K over 90 days
more than 73% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
21 funds added or opened last quarter
below 73% of Medical Devices
REVENUE
+15.8% year over year
more than 68% of Medical Devices
MARGIN
-48.4% net margin
below 72% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
EW HEALTHCARE PARTNERS FUND 2, L.P. disclosed a 5%+ stake (6.77%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -52.8%
-52.8%12M
-68%-45%-23%+0%2025-092025-102025-122026-032026-052026-072026-09 2025-11-17 · EW Healthcare Partners Fund 2-UGP, LLC bought $4.0M2026-08-14 · Getz Heather C bought $10.5K2026-08-17 · Getz Heather C bought $8.3K2026-06-09 · EW HEALTHCARE PARTNERS FUND 2, L.P. filed a 5%+ stake (6.77%)2026-06-09 · EW HEALTHCARE PARTNERS FUND 2-A, L.P. filed a 5%+ stake (10.46%)2026-06-09 · EW Healthcare Partners Fund 2-GP, L.P. filed a 5%+ stake (17.23%)2026-06-09 · EW Healthcare Partners Fund 2-UGP, LLC filed a 5%+ stake (17.23%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows a net $18.8K bought by insiders over 180 days, 21 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, TELA Bio, Inc. insiders bought a net $18.8K of stock across 205 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Getz Heather C
Chief Executive Officer
BUY
2026-08-17
12,500.0
$8.3K
Getz Heather C
Chief Executive Officer
BUY
2026-08-14
15,000.0
$10.5K
EW Healthcare Partners Fund 2-UGP, LLC
BUY
2025-11-17
3,604,000.0
$4.0M
Cuca Roberto
COO and CFO
BUY
2024-10-24
64,444.0
$145.0K
Talmo Paul
Chief Technology Officer
BUY
2024-10-24
22,222.0
$50.0K
205 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 200 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Nantahala Capital Management, LLC
11,788,228.0 sh
$8.8M
Essex Woodlands Management, Inc.
7,714,709.0 sh
$5.8M
Stonepine Capital Management, LLC
5,324,854.0 sh
$4.0M
SILVERARC CAPITAL MANAGEMENT, LLC
2,137,201.0 sh
$1.6M
VANGUARD CAPITAL MANAGEMENT LLC
1,568,218.0 sh
$1.2M
5%+ owners
13D = intent to influence · 13G = passive
EW HEALTHCARE PARTNERS FUND 2, L.P.
ACTIVIST 13D · 2026-06-09
6.77%
EW HEALTHCARE PARTNERS FUND 2-A, L.P.
ACTIVIST 13D · 2026-06-09
10.46%
EW Healthcare Partners Fund 2-GP, L.P.
ACTIVIST 13D · 2026-06-09
17.23%
EW Healthcare Partners Fund 2-UGP, LLC
ACTIVIST 13D · 2026-06-09
17.23%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Jacob Discovery Fund
$104.0K POSITION · AS OF 2026-02-28
0.6%
Small Cap Core Fund
$21.1K POSITION · AS OF 2026-03-31
0.0%
iShares Micro-Cap ETF
$53.1K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$3.8K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$149.1K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$242.4K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release
5
Not applicable
4 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$80.3M$69.3M$58.5M$41.4M
GROSS PROFIT$54.3M$46.5M$40.1M$27.0M
OPERATING INCOME$-33.8M$-34.1M$-44.1M$-39.0M
NET INCOME$-38.8M$-37.8M$-46.7M$-44.3M
EPS (DILUTED)-0.83-1.33-2.04-2.72
OPERATING CASH FLOW$-28.2M$-41.6M$-40.9M$-40.7M
CASH$50.8M$52.7M$46.7M$42.0M
LONG-TERM DEBT$55.7M$41.1M$40.5M$39.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →